Overview
EN ISO 10993-6:2026 - Biological evaluation of medical devices – Part 6: Tests for local effects after implantation – is an internationally recognized standard developed by CEN and ISO. This standard specifies requirements for preclinical assessment of the local tissue response following implantation of medical devices, or materials intended for use in such devices. The standard is a critical component within the ISO 10993 series and forms an essential part of the biological evaluation process for devices that are intended to breach skin or mucosal tissue.
EN ISO 10993-6:2026 is relevant for a range of medical devices and materials, including both solid and non-solid items (such as porous structures, gels, powders, and particulates), as well as absorbable, degradable, non-absorbable, or tissue-engineered medical products (TEMPs).
Key Topics
-
Purpose of Implantation Tests: The standard outlines methodologies for implanting test samples of medical device materials into appropriate animal models to evaluate local biological effects, focusing on tissue response rather than mechanical performance or systemic toxicity.
-
Sample and Control Material Selection: Emphasis is given to preparing test and control samples, ensuring these match the intended end-use state of the device (e.g., sterilized, processed, and finished as per ISO 10993-12 requirements).
-
Animal Model Selection: Guidance on choosing relevant animal species and implant sites to appropriately reflect the device's clinical application, minimizing animal use, and adhering to animal welfare requirements (per ISO 10993-2).
-
Evaluation Procedures: The document sets out standardized processes for macroscopic and microscopic assessment of tissue responses, including implant retrieval, histological sampling, and comparison with established control materials.
-
Test Periods: Details are provided for determining appropriate test durations, differentiating between short-term and long-term study timeframes, and tailoring intervals to the degradation profiles of absorbable materials.
-
Reporting Requirements: Comprehensive test reports are mandated, including details on sample preparation, animal models, implant sites, test periods, retrieval procedures, and evaluation findings.
Applications
The practical value of EN ISO 10993-6:2026 lies in its ability to help manufacturers and regulatory authorities:
- Verify Biocompatibility: Assess local tissue compatibility of novel medical device materials, especially where the device will contact breached tissue.
- Support Regulatory Submissions: Generate scientifically valid data to meet European and international regulatory requirements for medical device approval.
- Guide Product Development: Inform design and material selection to minimize adverse local tissue responses, enabling safer and more effective products.
- Evaluate a Wide Range of Devices: Applicable to surgical implants, resorbable scaffolds, dental materials, drug-device combination products, and tissue-engineered solutions.
- Reduce Animal Testing: By integrating endpoints (for example, combining local effects and systemic toxicity studies), the standard supports ethical research through reduction, refinement, and replacement strategies.
Related Standards
Implementing EN ISO 10993-6:2026 effectively involves consideration of other key standards in medical device biological evaluation:
- ISO 10993-1: Biological evaluation of medical devices – Part 1: Risk management and general testing strategy.
- ISO 10993-2: Animal welfare requirements during testing.
- ISO 10993-4: Selection of tests for interactions with blood.
- ISO 10993-11: Tests for systemic toxicity.
- ISO 10993-12: Sample preparation and reference materials.
- ISO 10993-16: Toxicokinetic study design for degradation products and leachables.
These related standards outline the broader framework for conducting robust biocompatibility assessments, ensuring comprehensive safety data for regulatory compliance.
By following EN ISO 10993-6:2026, organizations can ensure thorough and consistent evaluation of implantable medical devices, achieving both market access and patient safety objectives through standardized methods and scientifically sound risk assessments.